Elizabeth M Tunbridge

List of Publications by Year
in descending order

55 papers	4,060 citations	186265 28 h-index	168389 53 g-index
62 all docs	62 docs citations	62 times ranked	6376 citing authors

#	Article	IF	Citations
1	Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond. Biological Psychiatry, 2006, 60, 141-151.	1.3	656
2	Catechol-O-Methyltransferase Inhibition Improves Set-Shifting Performance and Elevates Stimulated Dopamine Release in the Rat Prefrontal Cortex. Journal of Neuroscience, 2004, 24, 5331-5335.	3.6	383
3	Tau Protein Is Required for Amyloid Î²-Induced Impairment of Hippocampal Long-Term Potentiation. Journal of Neuroscience, 2011, 31, 1688-1692.	3.6	275
4	Catechol-O-Methyltransferase (COMT): A Gene Contributing to Sex Differences in Brain Function, and to Sexual Dimorphism in the Predisposition to Psychiatric Disorders. Neuropsychopharmacology, 2008, 33, 3037-3045.	5.4	273
5	Tryptophan Depletion Alters the Decision-Making of Healthy Volunteers through Altered Processing of Reward Cues. Neuropsychopharmacology, 2003, 28, 153-162.	5.4	239
6	Computer Game Play Reduces Intrusive Memories of Experimental Trauma via Reconsolidation-Update Mechanisms. Psychological Science, 2015, 26, 1201-1215.	3.3	219
7	Catechol-o-Methyltransferase Enzyme Activity and Protein Expression in Human Prefrontal Cortex across the Postnatal Lifespan. Cerebral Cortex, 2007, 17, 1206-1212.	2.9	177
8	The Emerging Neurobiology of Bipolar Disorder. Trends in Neurosciences, 2018, 41, 18-30.	8.6	160
9	COMT Val158Met Genotype Determines the Direction of Cognitive Effects Produced by Catechol-O-Methyltransferase Inhibition. Biological Psychiatry, 2012, 71, 538-544.	1.3	124
10	How Cannabis Causes Paranoia: Using the Intravenous Administration of âˆ† 9 -Tetrahydrocannabinol (THC) to Identify Key Cognitive Mechanisms Leading to Paranoia. Schizophrenia Bulletin, 2015, 41, 391-399.	4.3	101
11	Long-read sequencing reveals the complex splicing profile of the psychiatric risk gene CACNA1C in human brain. Molecular Psychiatry, 2020, 25, 37-47.	7.9	98
12	Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Synapse, 2004, 51, 112-118.	1.2	85
13	Reduced cerebrovascular reactivity in young adults carrying the APOE Îµ4 allele. Alzheimer's and Dementia, 2015, 11, 648.	0.8	84
14	Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2â€ˆÃ—â€ˆ2 factorial randomised trial. Lancet Psychiatry,the, 2016, 3, 31-39.	7.4	84
15	It feels real: physiological responses to a stressful virtual reality environment and its impact on working memory. Journal of Psychopharmacology, 2019, 33, 1264-1273.	4.0	82
16	Which Dopamine Polymorphisms Are Functional? Systematic Review and Meta-analysis of COMT, DAT, DBH, DDC, DRD1â€“5, MAOA, MAOB, TH, VMAT1, and VMAT2. Biological Psychiatry, 2019, 86, 608-620.	1.3	67
17	Sexually Dimorphic Effects of Catechol-O-Methyltransferase (COMT) Inhibition on Dopamine Metabolism in Multiple Brain Regions. PLoS ONE, 2013, 8, e61839.	2.5	59
18	Genome-wide analysis of self-reported risk-taking behaviour and cross-disorder genetic correlations in the UK Biobank cohort. Translational Psychiatry, 2018, 8, 39.	4.8	57

#	Article	IF	Citations
19	The Catechol-O-Methyltransferase Gene. International Review of Neurobiology, 2010, 95, 7-27.	2.0	55
20	Catechol-O-methyltransferase (COMT) influences the connectivity of the prefrontal cortex at rest. NeuroImage, 2013, 68, 49-54.	4.2	52
21	Importance of the COMT Gene for Sex Differences in Brain Function and Predisposition to Psychiatric Disorders. Current Topics in Behavioral Neurosciences, 2010, 8, 119-140.	1.7	51
22	Changed Relative to What? Housekeeping Genes and Normalization Strategies in Human Brain Gene Expression Studies. Biological Psychiatry, 2011, 69, 173-179.	1.3	50
23	The genomic basis of mood instability: identification of 46 loci in 363,705 UK Biobank participants, genetic correlation with psychiatric disorders, and association with gene expression and function. Molecular Psychiatry, 2020, 25, 3091-3099.	7.9	48
24	Cellular calcium in bipolar disorder: systematic review and meta-analysis. Molecular Psychiatry, 2021, 26, 4106-4116.	7.9	46
25	Polymorphisms in the catecholâ€‹Oâ€‹methyltransferase (COMT) gene influence plasma total homocysteine levels. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 996-999.	1.7	45
26	Modulation of hippocampal theta and hippocampalâ€‹prefrontal cortex function by a schizophrenia risk gene. Human Brain Mapping, 2015, 36, 2387-2395.	3.6	44
27	Expression of multiple catechol-o-methyltransferase (COMT) mRNA variants in human brain. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 834-839.	1.7	36
28	Genetic moderation of the effects of cannabis: Catechol-O-methyltransferase (COMT) affects the impact of Î”⁹-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences. Journal of Psychopharmacology, 2015, 29, 1146-1151.	4.0	35
29	Voltage-gated calcium channel blockers for psychiatric disorders: genomic reappraisal. British Journal of Psychiatry, 2020, 216, 250-253.	2.8	35
30	Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Molecular Psychiatry, 2022, 27, 1339-1349.	7.9	31
31	Genetics of self-reported risk-taking behaviour, trans-ethnic consistency and relevance to brain gene expression. Translational Psychiatry, 2018, 8, 178.	4.8	29
32	Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibition. Journal of Psychopharmacology, 2012, 26, 1561-1568.	4.0	25
33	Induced Pluripotent Stem Cells in Psychiatry: An Overview and Critical Perspective. Biological Psychiatry, 2021, 90, 362-372.	1.3	23
34	Epistatic and Functional Interactions of Catechol-O-Methyltransferase (COMT) and AKT1 on Neuregulin1-ErbB Signaling in Cell Models. PLoS ONE, 2010, 5, e10789.	2.5	20
35	Distinct roles for dopamine clearance mechanisms in regulating behavioral flexibility. Molecular Psychiatry, 2021, 26, 7188-7199.	7.9	20
36	Genetic mouse models relevant to schizophrenia: Taking stock and looking forward. Neuropharmacology, 2012, 62, 1164-1167.	4.1	18

#	Article	IF	Citations
37	Genotype-Dependent Effects of COMT Inhibition on Cognitive Function in a Highly Specific, Novel Mouse Model of Altered COMT Activity. Neuropsychopharmacology, 2016, 41, 3060-3069.	5.4	18
38	Dissociable Catecholaminergic Modulation of Visual Attention: Differential Effects of Catechol-O-Methyltransferase and Dopamine Beta-Hydroxylase Genes on Visual Attention. Neuroscience, 2019, 412, 175-189.	2.3	17
39	The Oxford study of Calcium channel Antagonism, Cognition, Mood instability and Sleep (OxCaMS): study protocol for a randomised controlled, experimental medicine study. Trials, 2019, 20, 120.	1.6	17
40	Targeting synaptic plasticity in schizophrenia: insights from genomic studies. Trends in Molecular Medicine, 2021, 27, 1022-1032.	6.7	17
41	Decreased striatal dopamine in group II metabotropic glutamate receptor (mGlu2/mGlu3) double knockout mice. BMC Neuroscience, 2013, 14, 102.	1.9	16
42	Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: Analysis of the <scp>CEQUEL</scp> clinical trial. Bipolar Disorders, 2017, 19, 477-486.	1.9	11
43	Long read sequencing reveals novel isoforms and insights into splicing regulation during cell state changes. BMC Genomics, 2022, 23, 42.	2.8	11
44	Plasma glutathione suggests oxidative stress is equally present in earlyâ€•and lateâ€onset bipolar disorder. Bipolar Disorders, 2019, 21, 61-67.	1.9	10
45	Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia. CNS Drugs, 2022, 36, 1-16.	5.9	8
46	The Emerging Neurobiology of Bipolar Disorder. Focus (American Psychiatric Publishing), 2019, 17, 284-293.	0.8	7
47	Restrictions on drugs with medical value: Moving beyond stalemate. Journal of Psychopharmacology, 2018, 32, 1053-1055.	4.0	5
48	Brain-enriched CACNA1C isoforms as novel, selective targets for psychiatric indications. Neuropsychopharmacology, 2022, 47, 393-394.	5.4	5
49	Dopaminergic modulation of regional cerebral blood flow: An arterial spin labelling study of genetic and pharmacological manipulation of COMT activity. NeuroImage, 2021, 234, 117999.	4.2	5
50	Unraveling Mechanisms of Patient-Specific NRXN1 Mutations in Neuropsychiatric Diseases Using Human Induced Pluripotent Stem Cells. Stem Cells and Development, 2020, 29, 1142-1144.	2.1	3
51	Long read transcript profiling of ion channel splice isoforms. Methods in Enzymology, 2021, 654, 345-364.	1.0	2
52	Roadblock: improved annotations do not necessarily translate into new functional insights. Genome Biology, 2021, 22, 320.	8.8	2
53	New drug targets in psychiatry: Neurobiological considerations in the genomics era. Neuroscience and Biobehavioral Reviews, 2022, 139, 104763.	6.1	1
54	Benchmarking pluripotent stem cell-derived organoid models. Experimental Neurology, 2020, 330, 113333.	4.1	0

#	Article	IF	Citations
55	Catechol-O-methyltransferase activity does not influence emotional processing in men. Journal of Psychopharmacology, 2022, 36, 768-775.	4.0	0